{"nctId":"NCT02452060","briefTitle":"Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy","startDateStruct":{"date":"2014-10","type":"ACTUAL"},"conditions":["Pain","Postoperative Depression"],"count":90,"armGroups":[{"label":"treatment/placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo Comparator"]},{"label":"treatment","type":"EXPERIMENTAL","interventionNames":["Drug: Ketamine"]}],"interventions":[{"name":"Ketamine","otherNames":["ketalar"]},{"name":"Placebo Comparator","otherNames":["Saline Infusion"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Adults, \\>18 years, \\<65 years, who will undergo gastric bypass or sleeve gastrectomy.\n2. Subject is non-lactating and is either:\n\n   * Not of childbearing potential; or\n   * Of childbearing potential but is not pregnant at time of baseline as determined by pre-operative pregnancy testing.\n3. Subject is ASA physical status 1, 2, or 3.\n4. Subject who is deemed medically stable\n\nExclusion Criteria:\n\n1. \\<18 years of age; \\>65 years of age\n2. Pregnant or breastfeeding\n3. Does not speak or understand English (the study forms used are copy-righted in English)\n4. Cognitively impairment (by history) or clinical signs of altered mental status\n5. History of misuse or abuse of ketamine\n6. History of chest pain or chest pain in the PACU\n7. Use of a medication that interferes with metabolism of ketamine within the last 24 hours\n8. A diagnosis of schizophrenia and/ or a history of chronic antipsychotic medication use\n9. History of head trauma\n10. History of intracranial mass or hemorrhage\n11. History of stroke\n12. History of cardiac arrhythmia\n13. Subject for whom ketamine is contraindicated\n14. Unwillingness to give informed consent according to HIC guidelines","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Pain Scores","description":"VAS Scores will be assessed on Day of Surgery (DOS), Post-op Day (POD) 1, 2 and 7. If patients have been discharged, coordinators will contact patient by home.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.45","spread":".23"},{"groupId":"OG001","value":"1","spread":"0.18"}]}]}]},{"type":"SECONDARY","title":"Length of Stay During Hospitalization","description":"LOS will be recorded from medical record.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Opioid Usage Per Hour During the PACU Stay Before and After Ketamine Infusion","description":"Length of stay and opioid usage will be recorded from electronic medical chart","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Opioid Usage Per Day Throughout the Hospital Stay","description":"recorded from medical chart","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Time to Out of Bed to Chair (OOB)","description":"Patient will be asked to record and report the time to OOB","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Spirometry Use 4 Hours After the Termination of Ketamine Infusion","description":"Spirometry use will be assessed by a study team member to determine whether the patient is meeting the goal set by the surgical team 4 hours after ketamine infusion.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Serum Level of IL-1 After Ketamine Infusion","description":"changes in serum levels of IL-1, which will be collected at baseline (in the OR preoperatively), and 15 min and 4 hours after the termination of ketamine infusion.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Survey Scores - McGill's Short Form","description":"Change in survey scores -- McGill's short form","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Survey Scores - Becks Depression Index (BDI)","description":"Change in survey scores for Becks Depression Index (BDI)","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Survey Scores - QoR15","description":"Change in scores for Quality of Recovery 15 - QoR15","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Survey Scores - MADRS","description":"Change in scores for MADRS","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Serum Level of IL-6 After Ketamine Infusion","description":"changes in serum levels of IL-1, which will be collected at baseline (in the OR preoperatively), and 15 min and 4 hours after the termination of ketamine infusion.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Serum Level of TNF-Î± After Ketamine Infusion","description":"changes in serum levels of IL-1, which will be collected at baseline (in the OR preoperatively), and 15 min and 4 hours after the termination of ketamine infusion.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Serum Level of BDNF After Ketamine Infusion","description":"changes in serum levels of IL-1, which will be collected at baseline (in the OR preoperatively), and 15 min and 4 hours after the termination of ketamine infusion.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":46},"commonTop":["dizziness/lightheadedness","nausea","euphoria","visual hallucination","Dysphoria"]}}}